Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Celltrion received approval from the U.S. FDA for a supplemental Biologics License Application (sBLA) securing interchangeability status for Yuflyma, its Humira biosimilar. This designation allows Yuflyma to be substituted for the reference product at the pharmacy level without the intervention of a prescribing physician.
📊 Key Disclosure Content & Financial Highlights
- Overview
- Company: Celltrion, Inc. (Stock Code: 068270)
- Disclosure Type: Major Matters Report Related to Investment Decisions
- Subject: Approval of U.S. Supplemental sBLA for Interchangeability Designation of Yuflyma (CT-P17, Humira Biosimilar)
- Regulatory Body: U.S. Food and Drug Administration (FDA)
- Application & Approval Dates (Local Time): Application Date 2024-01-09 / Approval Date 2025-04-07
- Confirmation Date: 2025-04-12 (Receipt date of FDA approval letter)
- Product & Indication Details
- Product Name: Yuflyma (CT-P17, Active Ingredient: Adalimumab)
- Approved Indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn’s Disease (CD), Ulcerative Colitis (UC), Plaque Psoriasis (PsO), Hidradenitis Suppurativa (HS), Uveitis (UV)
- Key Details & Expected Effects
- Interchangeability Designation: Secures regulatory status allowing automatic substitution for the reference drug (Humira) at the pharmacy level without requiring physician intervention
- Underlying Data: Approval based on clinical trial data evaluating interchangeability in psoriasis patients
- Company Expectations: Anticipates market share expansion and enhanced marketing effectiveness in the U.S. market
- Additional Notes: Content will be utilized in future press releases and IR materials
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Approved Indications and Regulatory Status in Official Documents
This disclosure serves as official notification regarding FDA approval of Yuflyma’s interchangeability designation. Reviewing whether the specific indications and updated regulatory status granted by the approval are accurately reflected in the company’s official reporting documents is important for verifying the final regulatory documentation. Relevant details can be confirmed through subsequent periodic reports or official IR materials.
📢 Disclaimer & Source Notice
Source: This content was structured and generated based on official disclosure data from the Financial Supervisory Service’s DART system.
Investment Risk Warning: This material is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
